These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. The antithrombic drugs in clinical practice. Jacobs P; Knottenbelt E S Afr Med J; 1983 Jun; 63(26):997-1006. PubMed ID: 6344268 [TBL] [Abstract][Full Text] [Related]
47. Drug therapy: antiplatelet therapy (second of two parts). Weiss HJ N Engl J Med; 1978 Jun; 298(25):1403-6. PubMed ID: 349388 [No Abstract] [Full Text] [Related]
48. Antiplatelet drugs or dicoumarol: what is the most effective prophylaxis in occlusive arterial disease? Poliwoda H; Avenarius HJ Int Angiol; 1986; 5(3):169-80. PubMed ID: 2435823 [TBL] [Abstract][Full Text] [Related]
49. Human equivalent doses of platelet inhibitors and experimental atherosclerosis. Mittal SR; Mathur AK; Tandon R Int J Cardiol; 1990 May; 27(2):275-6. PubMed ID: 2365516 [TBL] [Abstract][Full Text] [Related]
50. [Present situation of therapy with platelet aggregation inhibitors]. Poliwoda H Acta Med Austriaca Suppl; 1982; 25():55-61. PubMed ID: 6958157 [No Abstract] [Full Text] [Related]
51. Effect of acetylsalicylic acid, other nonsteroidal anti-inflammatory agents, and dipyridamole on human blood platelets. Zucker MB; Peterson J J Lab Clin Med; 1970 Jul; 76(1):66-75. PubMed ID: 5425364 [No Abstract] [Full Text] [Related]
52. Inhibitors of platelet function in the prevention of arterial thrombosis. Harker LA Ser Haematol; 1975; 8(3):105-24. PubMed ID: 790583 [TBL] [Abstract][Full Text] [Related]
53. [Antiaggregants of thrombocytes in ischemic heart disease]. Beloev I ; Tomov I; TŭrnovskaR Vutr Boles; 1985; 24(5):1-6. PubMed ID: 2868572 [No Abstract] [Full Text] [Related]
54. Prevention of thromboembolic complications of valve prostheses by agents affecting platelet function. Wyss M; Diez C; Balavoine JF; Martin D; Bouvier CA Eur J Cardiol; 1978 Oct; 8(3):337-47. PubMed ID: 710491 [No Abstract] [Full Text] [Related]
55. Proceedings: Comparison of in vivo and in vitro effects of platelet function suppressing drugs. Buchanan M; Hirsh J Thromb Diath Haemorrh; 1975 Nov; 34(2):552. PubMed ID: 1198423 [No Abstract] [Full Text] [Related]
56. Platelet pharmacology in relation to thrombosis. Born GV Adv Cardiol; 1970; 4():161-74. PubMed ID: 4924078 [No Abstract] [Full Text] [Related]
57. Dipyridamole: a critical evaluation. Rivey MP; Alexander MR; Taylor JW Drug Intell Clin Pharm; 1984 Nov; 18(11):869-80. PubMed ID: 6389068 [TBL] [Abstract][Full Text] [Related]
58. Prevention of thrombosis with antiplatelet drugs. Kahn SB Am Fam Physician; 1980 May; 21(5):166-8. PubMed ID: 7377074 [No Abstract] [Full Text] [Related]
59. [Platelet antiaggregants and arteriopathies]. Cristol R J Mal Vasc; 1981; 6(3):237-41. PubMed ID: 7026714 [No Abstract] [Full Text] [Related]
60. Failure of sulphinpyrazone to affect platelet survival in patients with rheumatic heart valvular disease: a double blind study using 75Se-methionine labeled platelets. Fabris F; Casonato A; Randi ML; Schivazappa L; Schiavinato L; Girolami A Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(4):594-601. PubMed ID: 6196274 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]